Welcome To

M.A.G.I.C. CLINIC LTD

Care for People with Rare Metabolic and Genetic Diseases

New Research Studies:

GRIT STUDY

M.A.G.I.C. Clinic, the largest metabolic diseases clinic in Alberta, Canada is looking to learn better ways of managing virtual care for rare disease patients worldwide.

Status: Recruiting

Learn More

AVRO-RD-02-LTF01

A FOLLOW-UP STUDY OF SUBJECTS WITH TYPE 1 GAUCHER DISEASE WHO PREVIOUSLY RECEIVED AVR-RD-02 GENE THERAPY.

Status: Approved

REN001-201

A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)

Status: Site Selected

Ethics Applications being prepared

Enroll In a Study

ACTIVE RESEARCH STUDIES:

CONTACT US IF YOU ARE INTERESTED IN ENROLLING

Gene Therapy Trials:

AVRD-RD-01-201: Gene Therapy for Fabry disease – RECRUITING.

AVRD-RD-02-201: Gene Therapy for Gaucher disease – RECRUITING

301OTC02: OTC Gene Therapy Long Term Follow Up Study – RECRUITMENT COMPLETED

FACTS: Phase 1 Gene Therapy for Fabry disease – RECRUITMENT COMPLETED

Molecular Therapies:

MODIFY Open Label Extension – Open to only those patients that completed the main MODIFY study

SHP 609-203: Intrathecal Elaprase in patients with Hunter syndrome – RECRUITMENT COMPLETED.

EFC13738 / ELIKIDS: Eliglustat in Children with type I Gaucher disease – RECRUITING

ATB200-04: An Open-Label Study of Pharmacokinetics, Safety, Efficacy and Pharmacodynamics of ATB200/AT2221 in Pediatrics Subjects Aged 12 to < 18 years with Late-Onset Pompe Disease – RECRUITING

ATB200-07 OLE: Late Onset Pompe disease – RECRUITMENT COMPLETED

Gene Sequencing Studies:

EXOME SCREENING FOR CAUSES OF HYPERTROPHIC CARDIOMYOPATHY LIKE FABRY DISEASE – RECRUITING

Registry and Natural History Studies:

CFDI-NR (Canadian Fabry Disease Initiative Registry) – RECRUITING

FABRY REGISTRY – RECRUITING

GAUCHER DISEASE REGISTRY – RECRUITING

MPS1 REGISTRY – RECRUITING

POMPE DISEASE REGISTRY – RECRUITING

GRIT Study

Dietary Patterns and Supplement Use in Mitochondrial Disease – RECRUITING

Fabry Biomarker Switch ERT STUDY

Oudit Fabry Biomarker Study

Who we are

M.A.G.I.C stands for Metabolics and Genetics in Calgary. We are a medical clinic that specializes in looking after patients (children and adults) with rare diseases that are due to changes in their DNA. Things like Lysosomal Storage Diseases (Fabry disease, Gaucher disease, Pompe disease to name a few), Mitochondrial Diseases, and overall more than 2,000 known different genetic diseases.

Our Focus

We use a modern approach to diagnose and treat rare diseases with a team that cares about how well you do

Our Approach

We have technologies that can give you results on genetic testing in less than a week. That gives you the fastest access to Whole Exome Sequencing, Whole Genome Sequencing, and our unique Mitochondrial Genome Sequencing

Treatments

We look at finding those special medications that can make a difference. We have the largest clinic in Alberta for patients with lysosomal diseases needing enzyme therapies or spinal injection therapies

Clinical Trials

Our clinical trials units is dedicated to providing access to research therapies for rare metabolic and genetic diseases

Find out More

Meet Dr. Aneal Khan

Medical Geneticist

Dr. Khan was the first physician in the world to treat Fabry disease and Gaucher disease using Gene Therapy, the first in Canada to use Liver Cell Transplant and Gene Therapy to treat Urea Cycle Diseases and is experience in using research drugs injected directly into the spine.

Dr. Khan has extensive experience in diagnosing and treating mitochondrial diseases and published the largest clinical trial in Canada, called MITO-FIND, focusing on using DNA sequencing methods to diagnose mitochondrial disease. After having performed hundreds of muscle biopsies on children and adults, he worked with his team to develop a mitochondrial DNA sequencing method that can make a diagnosis from a cheek swab using Nanopore sequencing without the need to do a muscle biopsy in the majority of cases.

Meet Our Talented Team